B. Riley Securities Reiterates Buy on Agenus, Raises Price Target to $16
Agenus' Q3 Earnings Match Estimates, Revenues Miss Mark, Stock Down
Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026
Agenus Inc. (AGEN) Discusses BOT BAL Development and Planned Phase 3 ROBBIN Trial Transcript
Agenus Announces New Findings From Long-Term Survivor Analysis Of Phase 1b C-800-01 Trial Evaluating Botensilimab In Combination With Balstilimab In Heavily Pretreated Patients With MSS, mCRC Without Active Liver Metastases
Agenus: Q3 Earnings Snapshot
Agenus Targets Phase 3 Colon Cancer Trial as Financing Hinges on Enrollment Milestones
Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study
Agenus Q3 Sales $31.500M Beat $28.217M Estimate
Agenus to Participate in Rodman & Renshaw Virtual Fireside Chat
Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer
Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026
Agenus to Provide Third Quarter 2026 Financial Report and Development Update
Agenus Pivots BOT/BAL Strategy to Phase III Colon Cancer Trial
Agenus to Participate in Chardan’s 10th Annual Healthcare Investor Conference
Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer
Agenus Receives Marketion Authorization From Armenia For Botvymo To Treat Adult Patients With Microsatellite Stable Metastatic Colorectal Cancer
Reported Saturday, Agenus Says 25% Of Recurrent Ovarian Cancer Patients Treated With BOT+BAL Were Alive And Off All Therapy At Last Follow-Up, With 48% Estimated Three-Year Survival Among Evaluable Patients
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.